Life Science Entrepreneurs, Cardiologists, & Circulatory Support Experts


Eric S. Fain, M.D.

President & CEO

With over 30 years of experience in the medical device industry, Dr. Fain was the former Senior Vice President and Group President, Cardiovascular and Neuromodulation at Abbott following their acquisition of St. Jude Medical in 2017. Dr. Fain became Group President of St. Jude Medical in 2014. Dr. Fain received his M.D. from Stanford University School of Medicine.

Reynolds M. Delgado III, MD, FACC

Founder & Chief Medical Officer

Practicing cardiologist and leader in the field of heart failure. Medical Director, Mechanical Support Devices in Heart Failure, Texas Heart Institute; Advisory Board, Boston Scientific (LATITUDE HF monitoring system); Author on two NEJM articles that led to the FDA approval of the Heartmate II™ LVAD.

Jason Heuring, PhD

Chief Scientific Officer

Experienced venture-backed founder of three start-ups; McKinsey & Co. consultant with CV OR and cath-lab focused engagements; Ph.D. from Oxford University in Sensors, Sensor Fusion, Control Systems, and Artificial Vision.

Elisabeth (Beth) Neely

Senior Vice President, Clinical And Regulatory Affairs

Beth brings to Procyrion more than 20 years of experience as a global regulatory affairs leader, having played a key role in the approval of neuromodulation and cardiac devices. She has been integral in successful US and international registrations for clinical trials and commercial product approvals.

Av Edidin, Ph.D.

Senior Vice President, Development and Manufacturing

Av brings over 25 years of experience in the research, development, and manufacture of medical devices and has introduced commercial products in the long-bone orthopaedic, spinal fixation and ablation, and catheter instrumentation areas. He is named on over 15 U.S. and foreign patents. Av received his Ph.D. in Biomedical Engineering from Cornell University.

Katherine Cox

Vice President, Quality Assurance

Katherine is an experienced Quality Assurance professional, highly knowledgeable and skilled in Quality Engineering and in developing, implementing and maintaining Quality Management Systems compliant with 21 CFR 820, ISO 13485 and international regulations for successful 510k / CE Mark device registration and PMA approval.

Chris Durst, PhD

Vice President, Product Development

Accomplished bioengineer and medical device entrepreneur with extensive experience in structural heart research; experience in world-class labs in both the US and Europe, developing enabling technologies for the treatment of valve disease; BS with highest honors from the Georgia Institute of Technology; PhD in Bioengineering from Rice University.

Board of Directors

Gerhard “Gary” F. Burbach

Mr. Burbach, an accomplished medical device executive, joined Procyrion’s Board as an Independent Director and Chairman in February 2016. From January 2006 to September 2014, Mr. Burbach served as president, chief executive officer, and director of Thoratec Corporation (NASDAQ: THOR).

Eric S. Fain, M.D.

With over 30 years of experience in the medical device industry, Dr. Fain was the former Senior Vice President and Group President, Cardiovascular and Neuromodulation at Abbott following their acquisition of St. Jude Medical in 2017. Dr. Fain became Group President of St. Jude Medical in 2014. Dr. Fain received his M.D. from Stanford University School of Medicine.

Leo Linbeck, III

Leo Linbeck III is the Chairman and Founder of Fannin Innovation Studio. Leo is also President and CEO of the Aquinas Companies, LLC, which sponsored Fannin for five years to validate its model before bringing in outside investors for scale-up. Leo graduated from the University of Notre Dame with both Civil Engineering and Liberal Arts degrees and received a Master’s in Structural Engineering from the University of Texas. He earned his MBA from the Stanford University Graduate School of Business.

Carter Meyer

Carter Meyer is the founder and Managing Partner of View Ventures, a venture capital fund investing in medical and health technologies. For the 14 years years prior to that, Mr. Meyer was the Chief Executive Officer of SHD Management, LLC (“SHD”) which is the manager of three life science investment funds.

Marc Chaput

Marc Chaput is a Partner at Gravitas Healthcare, a strategic advisory firm focused on emerging growth medical device companies. Prior to Gravitas, he was a Director in Cowen & Co.'s health care investment banking group, and prior to that he worked in the health care group at Deutsche Bank. He is also on the Advisory Committee of Sweetwater Capital Partners and represents the State of Texas on the Procyrion board.

Jeff Bird

Jeff Bird has been a life science investor for nearly twenty years at Sutter Hill Ventures. In 2019, he formed Bluebird Ventures. Jeff received an MD and PhD (Cancer Biology) degree from Stanford Medical School, and was a Stanford undergraduate.

Scientific Advisory Board

Keith Aaronson, MD, MS

Keith Aaronson, MD, MS, is the Bertram Pitt, MD Collegiate Professor of Cardiovascular Medicine and Professor of Internal Medicine in the Division of Cardiovascular Medicine, University of Michigan Medical School, the Medical Director of the Cardiac Transplant Service and the Center for Circulatory Support and the Co-Director of the Heart Failure and Transplant Management Program for Michigan Medicine.

Jennifer Cowger, MD, MS

Jennifer Cowger, MD, MS is the Medical Director of the Mechanical Circulatory Support Program and Co-Director of the Cardiac Intensive Care Unit at Henry Ford Hospital. She is also an Associate Professor at Wayne State University in Detroit, Michigan. She attended medical school at Ohio State University, then completed her residency at Duke University and cardiology fellowship at the University of Michigan. She also holds a masters in statistics from the University of Michigan.

Matheen A. Khuddus, MD, FACC, FSCAI

Matheen Khuddus, MD is the Director of Cardiovascular Research at The Cardiac and Vascular Institute in Gainesville, Florida and Assistant Professor of Internal Medicine at the University of Central Florida. He is an Interventional Cardiologist and his clinical interests include the use of mechanical circulatory support in cardiogenic shock and high risk PCI and the endovascular treatment of peripheral arterial disease.

Manesh R. Patel, MD, FACC, FAHA, FSCAI

Manesh Patel, MD, Chief of the Division of Cardiology for Duke's Department of Medicine, is an associate professor of medicine, a member of the Duke Clinical Research Institute, and director of Interventional Cardiology and Cardiac Catheterization Labs across the Duke University Health System. His clinical interests include diagnostic and interventional coronary angiography, peripheral angiography, and endovascular intervention. He is involved in several clinical trials involving patients with cardiovascular disease and in cardiac imaging.

Sean Pinney, MD, FACC

Sean Pinney, MD is the Co-Director of the Heart and Vascular Center and Director of the Advanced Heart Failure, Transplant and Mechanical Circulatory Support Program at the University of Chicago Medicine. Pinney previously worked at Mount Sinai Hospital in New York, where he led the advanced heart failure and cardiac transplantation programs. He is a native of St. Louis, and he attended Georgetown University in Washington, D.C., for both his undergraduate and medical degrees.

Janani Rangaswami, MD, FACP, FCRS, FAHA

Janani Rangaswami, MD, FACP, FCRS, FAHA is an attending nephrologist and professor of medicine at the George Washington University School of Medicine and Health Sciences. She is the fellowship program director for the Division of Nephrology at GWU, as well as director of the cardiorenal program. She completed her residency and chief residency in Internal Medicine at Einstein Medical Center, Philadelphia and a fellowship in Nephrology at Weill Cornell Medical Center, NY.

Nir Uriel, MD, MSc

Nir Uriel, MD, MSc, an internationally recognized leader in heart failure, mechanical circulatory support, and heart transplantation, is Director of Advanced Heart Failure and Cardiac Transplantation at NewYork-Presbyterian. Dr. Uriel oversees heart failure programs at NewYork-Presbyterian’s campuses in Manhattan, Queens, Brooklyn, and Westchester, with a goal to increase accessibility of care for those with advanced heart failure throughout the New York area.

Prof. Stephen Worthley, MB, BS, PhD, FRACP, FACC, FCSANZ, FRCP

Prof. Stephen Worthley is Executive Manager of Cardiology at GenesisCare in mainland Australia, leading a network of over 80 cardiologists and 6 practices. This role enables him (with his passion and exceptional leadership capabilities) to help shape and direct the future of healthcare. He practices procedural work in structural heart disease one day per week at the Royal Adelaide Hospital and fosters the research program of the GenesisCare Research Network.